中枢性性早熟治疗期间的骨矿物质密度
Bone mineral density during treatment of central precocious puberty.
作者信息
Neely E K, Bachrach L K, Hintz R L, Habiby R L, Slemenda C W, Feezle L, Pescovitz O H
机构信息
Department of Pediatrics, Stanford University Medical Center, California 94305, USA.
出版信息
J Pediatr. 1995 Nov;127(5):819-22. doi: 10.1016/s0022-3476(95)70182-6.
Treatment of adults with gonadotropin releasing hormone analogs has resulted in rapid loss in bone mineral density (BMD). We measured lumbar and femoral neck BMD by dual-energy x-ray absorptiometry during 2 years of depot leuprolide therapy in 13 girls (mean age, 7.5 years; mean bone age, 10.9 years). At baseline, BMD was elevated for age and concordant with the advanced skeletal age. During therapy with gonadotropin releasing hormone analog, BMD values increased and BMD standard deviation scores for age and skeletal age did not change.
用促性腺激素释放激素类似物治疗成年人会导致骨矿物质密度（BMD）迅速下降。我们采用双能X线吸收法对13名女孩（平均年龄7.5岁；平均骨龄10.9岁）进行了为期2年的长效亮丙瑞林治疗，并测量了她们腰椎和股骨颈的骨矿物质密度。基线时，骨矿物质密度高于同龄人，且与提前的骨骼年龄相符。在促性腺激素释放激素类似物治疗期间，骨矿物质密度值升高，年龄和骨骼年龄的骨矿物质密度标准差分数未发生变化。
Zotero 插件